
Surrozen Investor Relations Material
Latest events

Q4 2022
Surrozen
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Surrozen Inc
Access all reports
Surrozen Inc., established in 2015, is a clinical-stage biotechnology firm at the forefront of developing novel therapeutics designed to selectively modulate the Wnt pathway for tissue repair and regeneration. The company's innovative approach involves the creation of targeted regenerative antibodies intended to repair a wide array of tissues and restore organ function damaged by serious diseases. Surrozen leverages advanced antibody engineering techniques and a deep understanding of Wnt pathway biology across various disease settings to design tissue-specific antibodies. These antibodies have the potential to regenerate tissue in a multitude of organs and tissues, addressing diseases such as liver, intestine, retinal, lacrimal gland, lung, cornea, pancreas, skin, and many others. The company is headquartered in South San Francisco, California, and its shares are listed on the Nasdaq.
Latest articles
)
Upcoming IPOs to Watch in 2025
Potential IPOs in 2025 include prominent names like Shein, Databricks, Klarna, eToro, and Figma, to name a few. Let's take a closer look.
23 May 2025
)
Figma: Collaborative Design Tool Ready for IPO
Figma, the popular design platform, is preparing for a potential IPO in 2025 as it continues to reshape the future of collaborative design.
22 May 2025
)
Companies That Had Their IPO in 2024: Momentum Increasing
2024 marked a steady year for IPOs, driven by strong markets, AI momentum, and high-profile listings across industries and regions.
22 May 2025
Ticker symbol
SRZN
Country
🇺🇸 United States